Teleflex will host conference calls on November 6 and 14, 2025, for financial results and Vascular Intervention updates.
Quiver AI Summary
Teleflex Incorporated will host a conference call on November 6, 2025, at 8:00 a.m. Eastern Time to discuss its third quarter financial results and provide an operational update. Participants can pre-register for dial-in details or access the call via a live audio webcast on the company’s website. An audio replay will be available after the call. Additionally, Teleflex will hold a virtual meeting on November 14, 2025, at 8:00 a.m. Eastern Time to review a recent acquisition in its Vascular Intervention business, which will include discussions on the strategic rationale and product portfolio. Teleflex aims to enhance healthcare through its diverse medical technologies and trusted brands. For more information, visit teleflex.com.
Potential Positives
- Teleflex will discuss its third quarter financial results and provide an operational update, which can enhance transparency and investor confidence.
- The planned virtual meeting on November 14, 2025, to review a recent business acquisition indicates growth and strategic development in the Vascular Intervention sector.
- The press release emphasizes Teleflex's commitment to improving health and quality of life, reinforcing its position as a dedicated leader in the healthcare industry.
- Teleflex showcases a diverse portfolio of trusted brands, highlighting its broad expertise and potential for continued innovation in various therapy areas.
Potential Negatives
- While announcing its upcoming conference call and acquisition, the press release may signal uncertainty or concerns regarding Teleflex's current financial performance and operational status, prompting the need for significant updates to investors.
- The focus on an acquisition may raise concerns about the associated risks and challenges with integrating new business operations, potentially indicating underlying issues in the existing company structure.
- Providing detailed information about a recent acquisition during a separate event could imply that the company is not fully confident in its internal operations and must seek external growth strategies.
FAQ
When is Teleflex's third quarter financial results conference call?
Teleflex will host a conference call on November 6, 2025, at 8:00 a.m. Eastern Time.
How can I participate in the Teleflex conference call?
You can pre-register through a provided link to receive the dial-in information and access the call on teleflex.com.
What is the purpose of the Vascular Intervention Virtual Meeting?
The meeting on November 14, 2025, will review Teleflex's recent Vascular Intervention business acquisition and its product portfolio.
Will there be a replay available for the conference call?
Yes, an audio replay will be available starting at 11:00 a.m. Eastern Time on November 6, 2025, on the Teleflex website and by phone.
What services does Teleflex provide in healthcare?
Teleflex offers medical technologies across several areas, including anesthesia, emergency medicine, interventional cardiology, and urology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TFX Congressional Stock Trading
Members of Congress have traded $TFX stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TFX stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 07/16 and 1 sale worth up to $15,000 on 07/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$TFX Insider Trading Activity
$TFX insiders have traded $TFX stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TFX stock by insiders over the last 6 months:
- LIAM KELLY (Chairman, President & CEO) purchased 1,500 shares for an estimated $172,605
- JAEWON RYU purchased 1,500 shares for an estimated $172,500
- STUART A RANDLE purchased 1,000 shares for an estimated $115,860
- ANDREW A KRAKAUER purchased 1,000 shares for an estimated $115,250
- GRETCHEN R HAGGERTY has made 2 purchases buying 500 shares for an estimated $57,375 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TFX Hedge Fund Activity
We have seen 196 institutional investors add shares of $TFX stock to their portfolio, and 239 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 1,850,171 shares (-55.8%) from their portfolio in Q2 2025, for an estimated $218,986,239
- MORGAN STANLEY removed 667,134 shares (-18.8%) from their portfolio in Q2 2025, for an estimated $78,961,980
- BLACKROCK, INC. removed 394,096 shares (-6.8%) from their portfolio in Q2 2025, for an estimated $46,645,202
- DIMENSIONAL FUND ADVISORS LP added 373,938 shares (+43.1%) to their portfolio in Q2 2025, for an estimated $44,259,301
- PZENA INVESTMENT MANAGEMENT LLC added 356,107 shares (+inf%) to their portfolio in Q2 2025, for an estimated $42,148,824
- WORLDQUANT MILLENNIUM ADVISORS LLC removed 346,131 shares (-93.4%) from their portfolio in Q2 2025, for an estimated $40,968,065
- QUBE RESEARCH & TECHNOLOGIES LTD added 303,521 shares (+100.1%) to their portfolio in Q2 2025, for an estimated $35,924,745
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TFX Analyst Ratings
Wall Street analysts have issued reports on $TFX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 05/05/2025
To track analyst ratings and price targets for $TFX, check out Quiver Quantitative's $TFX forecast page.
$TFX Price Targets
Multiple analysts have issued price targets for $TFX recently. We have seen 5 analysts offer price targets for $TFX in the last 6 months, with a median target of $135.0.
Here are some recent targets:
- Anthony Petrone from Mizuho set a target price of $135.0 on 08/01/2025
- Larry Biegelsen from Wells Fargo set a target price of $131.0 on 08/01/2025
- Shagun Singh from RBC Capital set a target price of $135.0 on 08/01/2025
- Richard Newitter from Truist Securities set a target price of $137.0 on 05/05/2025
- Patrick Wood from Morgan Stanley set a target price of $173.0 on 05/05/2025
Full Release
WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025.
To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com .
An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 6, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.
Vascular Intervention Virtual Meeting
On November 14, 2025, at 8:00 am Eastern Time, Teleflex will host a virtual meeting to review its recent Vascular Intervention business acquisition, with a focus on the strategic rationale and the comprehensive coronary and peripheral product portfolio.
To participate in the investor event, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com .
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com .
Contacts:
Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investors.teleflex.com
610-948-2836
